104 patents
Utility
Bispecific Binding Agents Binding to CLDN18.2 and CD3
18 Jan 24
The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
Matthew BERNETT, Alex NISTHAL, Gregory MOORE
Filed: 5 Jul 23
Utility
Optimized Antibody Variable Regions
14 Dec 23
The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components.
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Filed: 9 Jun 23
Utility
Antibodies That Bind PD-L1, PD-L2, And/or CD28
30 Nov 23
Provided herein are novel αPD-L1, αPD-L2, and αCD28 antibodies.
Gregory Moore, John R. Desjarlais, Michael Hedvat, Veronica Gusti Zeng, Juan Diaz
Filed: 13 Apr 23
Utility
Heterodimeric Antibodies That Bind CD3 and Tumor Antigens
16 Nov 23
The present invention is directed to novel heterodimeric antibodies.
Matthew Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
Filed: 27 Apr 23
Utility
Targeted Heterodimeric FC Fusion Proteins Containing IL-15/IL-15RA and NKG2D Antigen Binding Domains
26 Oct 23
The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL,-15Rα Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.
Matthew J. Bernett, John R. Desjarlais, Rajat Varma, Gregory Moore, Juan Diaz, Alex Nisthal, Ke Liu, Rumana Rashid, Eric Chang
Filed: 18 Oct 22
Utility
ANTI-CD28 X Anti-msln Antibodies
26 Oct 23
Provided herein are novel anti-CD28×anti-MSLN antibodies and methods of using such antibodies for the treatment of MSLN-associated cancers.
John R. Desjarlais, Gregory Moore, Michael Hedvat, Juan Diaz
Filed: 24 Feb 23
Utility
Optimized Antibodies That Target CD19
26 Oct 23
The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody.
Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
Filed: 21 Feb 23
Utility
TIM-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND TIM-3 ANTIGEN BINDING DOMAINS
19 Oct 23
The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a TIM-3 antibody fragment-Fc fusion protein.
Matthew J. Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
Filed: 13 Oct 22
Utility
ANTI-CD28 X Anti-psma Antibodies
12 Oct 23
Provided herein are novel anti-CD28×anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers.
John R. Desjarlais, Gregory Moore, Michael Hedvat, Juan Diaz, Veronica Gusti Zeng, Matthew Adam Dragovich, Joseph Erhardt, Theresa McDevitt, Fouad Moussa, Pankaj Seth, Fei Shen, Adam Zwolak
Filed: 3 May 23
Utility
LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
7 Sep 23
The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a LAG-3 antibody fragment-Fc fusion protein.
Matthew J. Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
Filed: 28 Apr 23
Utility
Novel Heterodimeric Proteins
7 Sep 23
The invention provides novel heterodimeric proteins including heterodimeric antibodies.
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Filed: 10 Mar 23
Utility
NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
31 Aug 23
The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE.
John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
Filed: 22 Dec 22
Utility
ANTI-CD28 Compositions
17 Aug 23
Provided herein are novel anti-CD28×anti-B7H3 (also referred to as “αCD28×αB7H3”) heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers.
John R. Desjarlais, Gregory Moore, Michael Hedvat, Juan Diaz, Veronica Gusti Zeng
Filed: 2 Dec 22
Utility
Methods and Compositions for Inhibiting CD32B Expressing Cells In IGG4-RELATED Diseases
20 Jul 23
The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
Filed: 11 Aug 22
Utility
Heterodimeric Antibodies That Bind ENPP3 and CD3
20 Jul 23
The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3).
Rumana Rashid, Umesh S. Muchhal, Gregory Moore, Alex Nishtal, Seung Chu, Sung-Hyung Lee, Yoon Kyung Kim
Filed: 3 Aug 22
Utility
BISPECIFIC HETERODIMERIC FUSION PROTEINS CONTAINING IL-15 - IL-15Ralpha Fc-FUSION PROTEINS AND IMMUNE CHECKPOINT ANTIBODY FRAGMENTS
13 Jul 23
The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
Filed: 13 Dec 22
Utility
IL15/IL15R Alpha Heterodimeric Fc-fusion Proteins for the Treatment of Cancer
18 May 23
The present disclosure provides methods of treating cancer by administering a heterodimeric protein comprising a first monomer comprising an IL15 protein-Fc domain fusion and a second monomer comprising an IL15Rα protein-Fc domain fusion.
Alexander Joachim Paul Ungewickell, Vittal Shivva, Rajbharan Yadav
Filed: 22 Jul 22
Utility
Bispecific Antibodies That Bind to B7H3 and NKG2D
18 May 23
Provided herein are bispecific antibodies that bind to B7H3 and NKG2D (e.g., antibodies having Fab-scFv-Fc, Fab2-scFv-Fc, mAb-scFv and stackFab2-scFv-Fc formats) or antigen binding fragments thereof.
Katrina Bykova, Matthew Faber, Matthew Bernett, Tian Zhang, Erik Pong, Kendra Avery, John Desjarlais
Filed: 7 Nov 22
Utility
IL-18-FC Fusion Proteins
11 May 23
Provided herein are IL18-Fc fusion proteins that include an empty-Fc domain and an IL18 protein connected to another Fc domain.
Alex Nisthal, John Desjarlais, Gregory Moore, Sung-Hyung Lee
Filed: 26 Jul 22
Utility
Bispecific Binding Agents Binding to CLDN18.2 and CD3
4 May 23
The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
Matthew BERNETT, Alex NISTHAL, Gregory MOORE
Filed: 6 Dec 22